Randomized Double Blind Parallel Groups Sequential, Placebo Controlled, Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (RLS)
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs BP 14979 (Primary)
- Indications Restless legs syndrome
- Focus Proof of concept; Therapeutic Use
- Sponsors Bioprojet
- 28 Jul 2020 Status changed from recruiting to discontinued as the sudy facing recruitment difficulties related to stringent eligibility criteria
- 09 Jul 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.
- 09 Jul 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.